201 related articles for article (PubMed ID: 31170942)
1. Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers.
Kremer A; Kremer T; Kristiansen G; Tolkach Y
BMC Urol; 2019 Jun; 19(1):46. PubMed ID: 31170942
[TBL] [Abstract][Full Text] [Related]
2. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis Identifying Wnt Ligands Gene Family for Biochemical Recurrence in Prostate Adenocarcinoma and Construction of a Nomogram.
Hu M; Xie J; Liu Z; Wang X; Liu M; Wang J
J Comput Biol; 2020 Dec; 27(12):1656-1667. PubMed ID: 32298604
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M
Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
[TBL] [Abstract][Full Text] [Related]
7. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
8. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
9. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
10. CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer.
Liang J; Zhang J; Ruan J; Mi Y; Hu Q; Wang Z; Wei B
Med Sci Monit; 2017 Nov; 23():5504-5514. PubMed ID: 29151113
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer.
Stinnesbeck M; Kristiansen A; Ellinger J; Hauser S; Egevad L; Tolkach Y; Kristiansen G
APMIS; 2021 Apr; 129(4):204-212. PubMed ID: 33455017
[TBL] [Abstract][Full Text] [Related]
12. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
Li X; Pasche B; Zhang W; Chen K
JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
[TBL] [Abstract][Full Text] [Related]
13. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
15. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
18. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
Rabien A; Fritzsche F; Jung M; Diamandis EP; Loening SA; Dietel M; Jung K; Stephan C; Kristiansen G
Tumour Biol; 2008; 29(1):1-8. PubMed ID: 18497543
[TBL] [Abstract][Full Text] [Related]
19. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis.
Sun J; Li S; Wang F; Fan C; Wang J
BMC Med Genet; 2019 Dec; 20(1):191. PubMed ID: 31791268
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
